RE.DOCTOR through its development of Non-Invasive Blood Glucose Monitoring (BGM) has engineered a pre-diabetes solution that is non-invasive, easily accessible, and low cost.

Diabetes and it’s related outcomes are expected to be a significant problem worldwide, with a projected 1 in 2 diabetic patients being undiagnosed by 2030.

The potential to vastly enhance chronic illness management such as Type 2 Diabetes Mellitus (T2DM) is still largely untapped.

By monitoring blood glucose levels, RE.DOCTOR provides the ability to pre-emptively identify individuals with pre-diabetes and potentially allow diabetics to dynamically manage their treatment for better blood glucose control.

RE.DOCTOR leverages the latest technological advancement in signal processing, PPG technologies, and artificial intelligence (AI) to assess the risk of impaired glucose regulation.

Inter-beat-interval data collection via the mobile phone app allows the AI model to compute the relevant digital biomarkers correlated with the symptoms of prediabetes or T2DM and display the risk of developing diabetes.

In 2021,

Approximately 537 million adults (20-79 years) are living with diabetes.

The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.
3 in 4 adults with diabetes live in low- and middle-income countries
Almost 1 in 2 (240 million) adults living with diabetes are undiagnosed
Diabetes caused 6.7 million deaths
Diabetes caused at least USD 966 billion dollars in health expenditure ? 9% of total spending on adults
More than 1.2 million children and adolescents (0-19 years) are living with type 1 diabetes
1 in 6 live births (21 million) are affected by diabetes during pregnancy
541 million adults are at increased risk of developing type 2 diabetes

Pre-Diabetes facts & figures

LAST UPDATE: 09/12/2021

The IDF Diabetes Atlas Tenth edition 2021 provides the latest figures, information and projections on diabetes worldwide.

Download the IDF Diabetes Atlas 10th Edition 2021 and other resources at www.diabetesatlas.org.

At present, type 1 diabetes cannot be prevented. The environmental pre-diabetes triggers that are thought to generate the process that results in the destruction of the body?s insulin-producing cells are still under investigation.

While there are a number of factors that influence the development of type 2 diabetes, it is evident that the most influential are lifestyle behaviours commonly associated with urbanization.

These include consumption of unhealthy foods and inactive lifestyles with sedentary behaviour. Studies from different parts of the world have established that lifestyle modification with physical activity and/or healthy diet can delay or prevent the onset of type 2 diabetes.

Modern lifestyles are characterised by physical inactivity and long sedentary periods. Community-based interventions can reach individuals and families through campaigns, education, social marketing and encourage physical activity both inside and outside school and the workplace. IDF recommends physical activity at least between three to five days a week, for a minimum of 30-45 minutes.

Taking a life course perspective is essential for preventing type 2 diabetes and its complications. Early in life, when eating and physical activity habits are established and when the long-term regulation of energy balance may be programmed, there is an especially critical window to prevent the development of overweight and reduce the risk of type 2 diabetes. Healthy lifestyles can improve health outcomes at later stages of life as well.

Pioneering the Future of Diabetes Prevention and Management

Insulin resistance is a serious health condition that can lead to type 2 diabetes, heart disease, and other chronic health problems. It is estimated that over 1 billion people worldwide have insulin resistance.

Traditional treatments for insulin resistance focus on lowering blood sugar levels, but they do not address the underlying cause of the problem. AI-driven lifestyle modification is a new approach to reversing insulin resistance that is based on the latest scientific research.

This approach uses artificial intelligence to create personalized plans for diet, exercise, and sleep that are designed to improve insulin sensitivity. These plans are based on each individual?s unique health data and lifestyle factors.

Early studies have shown that AI-driven lifestyle modification can be an effective way to reverse insulin resistance and improve overall health. In one study, participants who followed an AI-driven lifestyle modification plan for six months were able to reduce their body fat by 5%, increase their muscle mass by 3%, and lower their blood sugar levels by 15%.

AI-driven lifestyle modification is a safe and effective way to reverse insulin resistance and improve overall health. It is a personalized approach that is tailored to each individual?s needs.

Here are some of the benefits of AI-driven lifestyle modification:

Improves insulin sensitivity
Lowers blood sugar levels
Reduces body fat
Increases muscle mass
Improves heart health
Reduces the risk of type 2 diabetes and other chronic health problems

If you are interested in learning more about AI-driven lifestyle modification, please talk to RE.DOCTOR

Learn the benefits of combining medication with digital diabetes therapeutics

Pharmaceutical Companies Embrace Digital Diabetes Therapeutics (DTx) with RE.DOCTOR?s Innovative Solutions

In the ever-evolving healthcare landscape, pharmaceutical companies are continuously seeking innovative ways to enhance their treatment offerings. In this pursuit, digital therapeutics (DTx) have emerged as a transformative force, offering a personalized and data-driven approach to complement traditional pharmacotherapy. Leading the charge in this realm is RE.DOCTOR, a pioneer in DTx solutions, empowering pharmaceutical companies to seamlessly integrate DTx into their treatment strategies.

RE.DOCTOR?s comprehensive DTx platform seamlessly integrates with existing pharmaceutical products, providing a holistic approach to patient care. This integration enables seamless data exchange between DTx and pharmacotherapy, fostering a deeper understanding of patient responses and treatment outcomes. By leveraging RE.DOCTOR?s DTx solutions, pharmaceutical companies can:

- Enhance patient engagement and adherence through personalized interventions
- Provide real-time monitoring of patient progress and treatment efficacy
- Gather valuable data to inform future drug development and clinical trials

The integration of RE.DOCTOR?s DTx solutions into pharmaceutical treatment plans offers a multitude of benefits for patients. DTx can provide:

- Personalized guidance and support for lifestyle modifications
- Remote monitoring and symptom management
- Enhanced self-efficacy and empowerment in managing their health conditions

Through its collaboration with pharmaceutical companies, RE.DOCTOR is revolutionizing the healthcare industry, paving the way for a future where DTx seamlessly complements pharmacotherapy to deliver personalized, data-driven, and patient-centric care.

Additional resources:

The American Diabetes Association: https://www.diabetes.org/
The National Institute of Diabetes and Digestive and Kidney Diseases: https://www.niddk.nih.gov/
The Centers for Disease Control and Prevention: https://www.cdc.gov/

This study demonstrated that smartphone-measured PPG, analyzed with deep learning, can be used as a noninvasive digital biomarker of prevalent diabetes.

Свяжитесь с нами, чтобы получить любую помощи и информации

Позовите на помощь:

North America: +1-307-278-9811

Европа: +995-598-230-563

Напишите нам для получения информации

[email protected]

Наши решения не заменяют услуги медицинского специалиста, и наши решения не диагностируют, не предотвращают и не лечат какие-либо заболевания.

Pre-diabetes - RE.DOCTOR